Onconova Therapeutics, Inc. filed its 10-K on Mar 30, 2023 for the period ending Dec 31, 2022. In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.6406 USD | +0.14% | -1.46% | -14.08% |
May. 07 | Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy | CI |
Apr. 04 | North American Morning Briefing : Focus Turns to -2- | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.08% | 13.49M | |
+41.14% | 54.04B | |
+43.57% | 41.96B | |
-1.23% | 41.92B | |
-7.59% | 28.35B | |
+12.42% | 26.35B | |
-22.19% | 19B | |
+7.67% | 13B | |
+28.84% | 12.28B | |
+24.68% | 12.19B |
- Stock Market
- Equities
- TRAW Stock
- News Traws Pharma, Inc.
- Onconova Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt